BUPROPION HYDROCHLORIDE | A206122 | SCIEGEN PHARMACEUTICALS INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Yichang Humanwell Pharmaceutical Co., Ltd. FDA-2022-P-0614 Yichang Humanwell Pharmaceutical Co., Ltd. filed this citizen petition on April 18, 2022, requesting that the FDA determine whether the reference listed drug ZYBAN (bupropion hydrochloride sustained-release tablets, 150 mg) under NDA 020711 held by GlaxoSmithKline was voluntarily withdrawn from comm | 505(q) | 2022-04-19 | Denied | Yichang Humanwell Pharmaceutical Co. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.